- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Buy the Dip
U.S. Pharmaceuticals & Biotech Buy the Dip
UPDATED Nov 28, 2023
Companies which may present a buying opportunity after a dip in share price.
84 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
| MLABMesa Laboratories | US$87.63 | -1.0% | -46.9% | US$466.1m | US$115.00 | PS2.2x | E110.0% | 0.7% | ||
| MDXGMiMedx Group | US$7.89 | 9.4% | 155.3% | US$921.6m | US$11.65 | PS3x | E49.2% | n/a | ||
| ILMNIllumina | US$96.54 | 0.6% | -53.7% | US$15.0b | US$153.35 | PS3.4x | E80.3% | n/a | ||
| RCELAVITA Medical | US$10.77 | 5.9% | 65.2% | US$277.3m | US$24.52 | PS6.1x | E47.8% | n/a | ||
| OGNOrganon | US$11.30 | 2.4% | -54.7% | US$2.9b | US$20.33 | PE4.9x | E24.5% | 9.9% | ||
| ELANElanco Animal Health | US$11.99 | 1.8% | -2.1% | US$5.9b | US$13.33 | PS1.4x | E96.5% | n/a | ||
| ASRTAssertio Holdings | US$1.15 | -3.4% | -60.9% | US$112.7m | US$3.88 | PB0.6x | E105.2% | n/a | ||
| AMRNAmarin | US$0.74 | -3.2% | -34.7% | US$317.2m | US$2.05 | PB0.5x | E42.4% | n/a | ||
| BIOBio-Rad Laboratories | US$304.40 | -0.6% | -23.8% | US$8.9b | US$444.60 | PS3.3x | E57.6% | n/a | ||
| AYTUAytu BioPharma | US$2.38 | -3.1% | -40.6% | US$14.0m | US$5.00 | PB0.4x | E95.7% | n/a | ||
| MCRBSeres Therapeutics | US$1.13 | 8.1% | -83.0% | US$149.9m | US$8.54 | PS1.1x | E35.9% | n/a | ||
| CBUSCibus | US$13.45 | 8.0% | 79.0% | US$254.6m | US$22.00 | PS297.1x | E18.6% | n/a | ||
| ARQTArcutis Biotherapeutics | US$2.04 | 7.9% | -88.0% | US$185.0m | US$11.17 | PS3.9x | E42.6% | n/a | ||
| TBIOTelesis Bio | US$0.40 | 34.5% | -71.2% | US$10.3m | US$4.00 | PB0.7x | E60.9% | n/a | ||
| IMABI-Mab | US$1.55 | 2.0% | -56.1% | US$127.0m | US$25.68 | PB0.4x | E26.1% | n/a | ||
| BMYBristol-Myers Squibb | US$48.92 | 0.9% | -38.1% | US$99.7b | US$64.13 | PE12x | E11.4% | 4.7% | ||
| IFRXInflaRx | US$1.37 | -6.2% | -47.1% | US$82.4m | US$10.13 | PS1207.7x | E50.0% | n/a | ||
| RZLTRezolute | US$0.76 | -5.4% | -53.6% | US$30.7m | US$7.60 | PB0.3x | E34.7% | n/a | ||
| ADCTADC Therapeutics | US$0.73 | 0.8% | -78.4% | US$58.4m | US$8.00 | PE-0.3x | E16.1% | n/a | ||
| TKNOAlpha Teknova | US$2.07 | -4.6% | -55.4% | US$83.7m | US$4.83 | PS2.3x | E31.8% | n/a | ||
| CARMCarisma Therapeutics | US$2.37 | -3.1% | n/a | US$98.1m | US$10.00 | PS6.6x | E9.6% | n/a | ||
| RCKTRocket Pharmaceuticals | US$22.41 | 2.5% | 23.9% | US$2.1b | US$51.75 | PB3.7x | E56.9% | n/a | ||
| RVNCRevance Therapeutics | US$7.06 | -2.4% | -67.7% | US$605.9m | US$26.92 | PS2.9x | E58.0% | n/a | ||
| AGENAgenus | US$0.70 | 3.4% | -73.2% | US$251.9m | US$6.67 | PS2.7x | E8.6% | n/a |